About AIRNA
AIRNA is a Healthcare company based in Cambridge (United States) founded in 2021 by Jin Billy Li, Thorsten Stafforst, and Tobias Merkle. AIRNA has raised $245 million across 3 funding rounds from investors including ARE, RTW Investments and Arch Venture Partners. Its chief executive, as recorded, is Kris Elverum. AIRNA offers products and services including RNA Editing Therapeutics and AIR-001. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is AIRNA Corporation. Its competitors include BridgeBio, Spark Therapeutics and Alnylam; 3 of its 3 listed competitors have raised funding.
Company details
Developer of gene therapies for rare and common diseases. It offers RNA editing therapeutics based on a platform RESTORE to treat the inherited genetic disease alpha-1 antitrypsin deficiency (AATD).
- Total Equity Funding$245M (USD)
in 3 rounds
- Latest Funding Round$155M (USD), Series B
Apr 2025
- InvestorsARE
& 10 more
Products & Services of AIRNA
AIRNA offers a comprehensive portfolio of products and services, including RNA Editing Therapeutics and AIR-001.
Develops medicines for functional cures in rare diseases
RNA editing product for Alpha-1 antitrypsin deficiency treatment
Funding Insights of AIRNA
AIRNA has successfully raised a total of $245M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $155 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $245M
- Total Rounds 3
- Last Round Series B — $155M
- First Round $30M
(Sep 2023)
- Investors Count 11
All 3 funding rounds of AIRNA with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2025 | $155M | Series B | – | Venrock, Forbion | |
| Jul 2024 | $60M | Series A | – | Forbion | |
| Sep 2023 | $30M | Series A | – | Arch Venture Partners |
11 investors in total: 11 institutional.
Investors in AIRNA
AIRNA has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, RTW Investments and Arch Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
Venture capital firm focused on lifescience and healthcare sectors | forbion.com | Naarden, Netherlands | ||
Life Sciences focused VC firm investing in the US | 2010 | rtwfunds.com | New York, United States | |
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
PE firm investing in the US | nextechinvest.com | Zurich, Switzerland | ||
Tech startups are invested in by this venture capital firm. | nd.capital | Woodside, United States | ||
| onoventure.com | ||||
Investment and advisory services are provided for life sciences. | 2017 | novalislifesciences.com | Portsmouth, USA | |
| codoncapital.com | ||||
Investment and consultation services in healthcare and life sciences are delivered by the company. | fti-jp.com |
Investor details for AIRNA
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of AIRNA
26 people are tracked at AIRNA (22 in leadership, 4 in team).
| Name | Role | Group |
|---|---|---|
Jin Billy Li | Co-Founder | Leadership |
Thorsten Stafforst | Co-Founder | Leadership |
Tobias Merkle | Co-Founder | Leadership |
Kris Elverum | CEO | Leadership |
Allison Dorval | CFO | Leadership |
Anand Deshpande | Director, Quality | Leadership |
Joyce Zhao | Director, Analytical Development | Leadership |
Anindya Sen | Vice President, Head Of Pre-clinical Development | Leadership |
Andrea Armstrong | Interim Chief People Officer | Leadership |
Namita Bisaria | Vice President, Strategy & Program Management | Leadership |
Patrick Foster | Vice President Of CMC | Leadership |
Lena Fischer | VP Finance & Operations | Leadership |
Devyn Smith | VP Research & Managing Director | Leadership |
Kaiko Kunii | VP Research & Managing Director | Leadership |
Paul Vogel | VP Research & Managing Director | Leadership |
Josh Brumm | VP Research & Managing Director | Leadership |
Rodger Novak | VP Research & Managing Director | Leadership |
Ina Gerber | Associate Director HR & Finance | Leadership |
Jacob Elkins | Chief Medical Officer | Leadership |
Laleh Jafarpour | Associate Director Of CMC | Leadership |
6 more people are available in the full profile.
Complete people profiles for AIRNA
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of AIRNA
3 dated milestones of AIRNA across 4 years, from founding to its latest funding, stage changes and deals.
- Founded AIRNA is founded.
- Funding First funding round of $30.0M.
- Funding Latest funding round, Series B, of $155.0M.
Competitors of AIRNA
AIRNA has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Spark Therapeutics and Alnylam.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. |
Detailed competitors of AIRNA
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of AIRNA
The website of AIRNA (airna.com) receives about 3K visits a month.
- Monthly visits3K
▼ 30.3% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as AIRNA (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Airna
Complete news archive for AIRNA
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AIRNA
AIRNA was founded in 2021 and raised its 1st funding round 2 years after it was founded.
AIRNA is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Kris Elverum is the CEO of AIRNA, as recorded in our data.
AIRNA is a funded company, having raised a total of $245M across 3 funding rounds to date. The company's 1st funding round was a Series A of $30M, raised on Sep 2023.
Developer of gene therapies for rare and common diseases. It offers RNA editing therapeutics based on a platform RESTORE to treat the inherited genetic disease alpha-1 antitrypsin deficiency (AATD).
AIRNA's top competitors include Spark Therapeutics, BridgeBio and Alnylam.
AIRNA offers RNA Editing Therapeutics and AIR-001.
AIRNA has 11 investors. Key investors include ARE, RTW Investments, Arch Venture Partners, Venrock, and Forbion.
AIRNA operates through Airna Corporation.